Ernie Bush

Dr. Bush has spent over 27 years working in the field of biomedical R&D most of which working in preclinical safety departments for major pharmaceutical companies.  From 1992 to 2005 he worked at Hoffmann-La Roche, Inc. and for the last 5 years of that time he led their Non-Clinical Drug Safety Department.  This department was comprised of:  Drug Metabolism, Non-Clinical Pharmacokinetics, Bioanalytical, Toxicology (including Safety Pharmacology and Teratology), and Pathology.  The scope of their responsibilities spanned from early Discovery support through to NDA with particular emphasis on providing an integrated safety assessment to project teams and senior management.Although Dr. Bush’s graduate training and early career focused on bioanalytics and drug metabolism, he has always had a special interest in how pharma safety data was collected, managed and interpreted; this interest has evolved into a major job function due in part to the exploding volume of safety data generated in today’s R&D environment.  Consequently, Dr. Bush has been asked to lead several global initiatives on safety information management practices, including a global safety LIMS system at Roche and a global information repository for toxicogenomics data for the International Life Sciences Institute (ILSI).    Since joining DSEC in 2005, Dr. Bush has been the guiding force behind collaborative technology evaluations in the pharmaceutical safety space.  These projects bring together experts from multiple companies to improve the economics and effectiveness of how the industry conducts preclinical safety evaluations.  Therefore, his in-depth knowledge and broad global experience in both the informatics and safety assessment fields has made him a unique leader in today’s complex drug development landscape.